{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T22:29:56Z","timestamp":1790980196289,"version":"4.1.0"},"reference-count":106,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","cell.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Pharmacological Sciences"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1016\/j.tips.2017.03.010","type":"journal-article","created":{"date-parts":[[2017,4,23]],"date-time":"2017-04-23T01:03:37Z","timestamp":1492909417000},"page":"541-555","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":85,"title":["Tipping Points and Endogenous Determinants of Nigrostriatal Degeneration by MPTP"],"prefix":"10.1016","volume":"38","author":[{"given":"Stefan","family":"Schildknecht","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donato A.","family":"Di Monte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regina","family":"Pape","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Tieu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel","family":"Leist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tips.2017.03.010_bib0005","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1126\/science.6823561","article-title":"Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis","volume":"219","author":"Langston","year":"1983","journal-title":"Science"},{"key":"10.1016\/j.tips.2017.03.010_bib0010","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/S0022-3565(25)20491-8","article-title":"Biotransformation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in primary cultures of mouse astrocytes","volume":"258","author":"Di Monte","year":"1991","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.tips.2017.03.010_bib0015","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/glia.440050108","article-title":"Production and disposition of 1-methyl-4-phenylpyridinium in primary cultures of mouse astrocytes","volume":"5","author":"Di Monte","year":"1992","journal-title":"Glia"},{"key":"10.1016\/j.tips.2017.03.010_bib0020","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/311467a0","article-title":"Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors","volume":"311","author":"Heikkila","year":"1984","journal-title":"Nature"},{"key":"10.1016\/j.tips.2017.03.010_bib0025","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1073\/pnas.82.7.2173","article-title":"Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity","volume":"82","author":"Javitch","year":"1985","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.tips.2017.03.010_bib0030","doi-asserted-by":"crossref","first-page":"7585","DOI":"10.1016\/S0021-9258(19)57434-8","article-title":"Energy-dependent uptake of N-methyl-4-phenylpyridinium, the neurotoxic metabolite of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, by mitochondria","volume":"261","author":"Ramsay","year":"1986","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.tips.2017.03.010_bib0035","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.taap.2009.07.027","article-title":"Requirement of a dopaminergic neuronal phenotype for toxicity of low concentrations of 1-methyl-4-phenylpyridinium to human cells","volume":"241","author":"Schildknecht","year":"2009","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.tips.2017.03.010_bib0040","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1111\/j.1471-4159.2011.07255.x","article-title":"Rapid, complete and large-scale generation of post-mitotic neurons from the human LUHMES cell line","volume":"119","author":"Scholz","year":"2011","journal-title":"J Neurochem."},{"key":"10.1016\/j.tips.2017.03.010_bib0045","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1007\/s10534-012-9525-y","article-title":"The dopamine metabolite aminochrome inhibits mitochondrial complex I and modifies the expression of iron transporters DMT1 and FPN1","volume":"25","author":"Aguirre","year":"2012","journal-title":"Biometals"},{"key":"10.1016\/j.tips.2017.03.010_bib0050","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.neuro.2011.12.007","article-title":"Uncoupling of ATP-depletion and cell death in human dopaminergic neurons","volume":"33","author":"P\u00f6ltl","year":"2012","journal-title":"Neurotoxicology"},{"key":"10.1016\/j.tips.2017.03.010_bib0055","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1111\/j.1471-4159.2006.04333.x","article-title":"Mechanism of toxicity of pesticides acting at complex I: relevance to environmental etiologies of Parkinson\u2019s disease","volume":"100","author":"Sherer","year":"2007","journal-title":"J. Neurochem."},{"key":"10.1016\/j.tips.2017.03.010_bib0060","doi-asserted-by":"crossref","first-page":"10756","DOI":"10.1523\/JNEUROSCI.23-34-10756.2003","article-title":"Mechanism of toxicity in rotenone models of Parkinson\u2019s disease","volume":"23","author":"Sherer","year":"2003","journal-title":"J. Neurosci."},{"key":"10.1016\/j.tips.2017.03.010_bib0065","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1523\/JNEUROSCI.12-05-01658.1992","article-title":"Transgenic mice with increased Cu\/Zn-superoxide dismutase activity are resistant to N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity","volume":"12","author":"Przedborski","year":"1992","journal-title":"J. Neurosci."},{"key":"10.1016\/j.tips.2017.03.010_bib0070","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1093\/jnen\/59.1.53","article-title":"Enhanced N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity in mice deficient in CuZn-superoxide dismutase or glutathione peroxidase","volume":"59","author":"Zhang","year":"2000","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.tips.2017.03.010_bib0075","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/1742-2094-10-143","article-title":"Activation of microglia induces symptoms of Parkinson\u2019s disease in wild-type, but not in IL\u20131 knockout mice","volume":"10","author":"Tanaka","year":"2013","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.tips.2017.03.010_bib0080","doi-asserted-by":"crossref","first-page":"3328","DOI":"10.1523\/JNEUROSCI.5321-06.2007","article-title":"Involvement of interferon-gamma in microglial-mediated loss of dopaminergic neurons","volume":"27","author":"Mount","year":"2007","journal-title":"J. Neurosci."},{"key":"10.1016\/j.tips.2017.03.010_bib0085","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1096\/fj.02-0216fje","article-title":"Mice deficient in TNF receptors are protected against dopaminergic neurotoxicity: implications for Parkinson\u2019s disease","volume":"16","author":"Sriram","year":"2002","journal-title":"FASEB J."},{"key":"10.1016\/j.tips.2017.03.010_bib0090","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1242\/jcs.114439","article-title":"A novel Drp1 inhibitor diminishes aberrant mitochondrial fission and neurotoxicity","volume":"126","author":"Qi","year":"2013","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.tips.2017.03.010_bib0095","doi-asserted-by":"crossref","first-page":"5244","DOI":"10.1038\/ncomms6244","article-title":"Drp1 inhibition attenuates neurotoxicity and dopamine release deficits in vivo","volume":"5","author":"Rappold","year":"2014","journal-title":"Nat. Commun."},{"key":"10.1016\/j.tips.2017.03.010_bib0100","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s12035-014-8893-4","article-title":"The impact of mitochondrial fusion and fission modulation in sporadic Parkinson\u2019s disease","volume":"52","author":"Santos","year":"2015","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.tips.2017.03.010_bib0105","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1111\/j.1474-9726.2011.00721.x","article-title":"DLP1-dependent mitochondrial fragmentation mediates 1-methyl-4-phenylpyridinium toxicity in neurons: implications for Parkinson\u2019s disease","volume":"10","author":"Wang","year":"2011","journal-title":"Aging Cell"},{"key":"10.1016\/j.tips.2017.03.010_bib0110","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.ejphar.2014.11.038","article-title":"The adenosine A2A receptor antagonist, istradefylline enhances the anti-parkinsonian activity of low doses of dopamine agonists in MPTP-treated common marmosets","volume":"747","author":"Uchida","year":"2015","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.tips.2017.03.010_bib0115","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.neuroscience.2015.05.041","article-title":"Voxel-based morphometry of the marmoset brain: In vivo detection of volume loss in the substantia nigra of the MPTP-treated Parkinson\u2019s disease model","volume":"300","author":"Hikishima","year":"2015","journal-title":"Neuroscience"},{"key":"10.1016\/j.tips.2017.03.010_bib0120","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1006\/neur.1996.0041","article-title":"The neurotoxin MPTP causes degeneration of specific nucleus A8, A9 and A10 dopaminergic neurons in the mouse","volume":"5","author":"German","year":"1996","journal-title":"Neurodegeneration"},{"key":"10.1016\/j.tips.2017.03.010_bib0125","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1002\/ana.410320510","article-title":"Disease-specific patterns of locus coeruleus cell loss","volume":"32","author":"German","year":"1992","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.tips.2017.03.010_bib0130","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/0014-5793(85)81028-0","article-title":"Serotonergic conversion of MPTP and dopaminergic accumulation of MPP+","volume":"189","author":"Shen","year":"1985","journal-title":"FEBS Lett."},{"key":"10.1016\/j.tips.2017.03.010_bib0135","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1042\/bj1810007","article-title":"The vectorial orientation of human monoamine oxidase in the mitochondrial outer membrane","volume":"181","author":"Russell","year":"1979","journal-title":"Biochem. J."},{"key":"10.1016\/j.tips.2017.03.010_bib0140","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0306-4522(89)90243-1","article-title":"Histochemical localization of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine oxidation in the mouse brain","volume":"28","author":"Vincent","year":"1989","journal-title":"Neuroscience"},{"key":"10.1016\/j.tips.2017.03.010_bib0145","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/1055-8330(95)90015-2","article-title":"Time course and morphology of dopaminergic neuronal death caused by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine","volume":"4","author":"Jackson-Lewis","year":"1995","journal-title":"Neurodegeneration"},{"key":"10.1016\/j.tips.2017.03.010_bib0150","doi-asserted-by":"crossref","first-page":"4119","DOI":"10.1111\/bph.13193","article-title":"Prevention of the degeneration of human dopaminergic neurons in an astrocyte co-culture system allowing endogenous drug metabolism","volume":"172","author":"Efremova","year":"2015","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.tips.2017.03.010_bib0155","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S0167-4889(98)00071-8","article-title":"MPP+ toxicity and plasma membrane dopamine transporter: study using cell lines expressing the wild-type and mutant rat dopamine transporters","volume":"1404","author":"Kitayama","year":"1998","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.tips.2017.03.010_bib0160","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1089\/ars.2015.6297","article-title":"Preferential extracellular generation of the active parkinsonian toxin MPP+ by transporter-independent export of the intermediate MPDP+","volume":"23","author":"Schildknecht","year":"2015","journal-title":"Antioxid. Redox Signal."},{"key":"10.1016\/j.tips.2017.03.010_bib0165","doi-asserted-by":"crossref","first-page":"8043","DOI":"10.1073\/pnas.0900358106","article-title":"The organic cation transporter-3 is a pivotal modulator of neurodegeneration in the nigrostriatal dopaminergic pathway","volume":"106","author":"Cui","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.tips.2017.03.010_bib0170","doi-asserted-by":"crossref","first-page":"20766","DOI":"10.1073\/pnas.1115141108","article-title":"Paraquat neurotoxicity is mediated by the dopamine transporter and organic cation transporter-3","volume":"108","author":"Rappold","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.tips.2017.03.010_bib0175","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/0006-291X(84)91293-2","article-title":"Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase","volume":"120","author":"Chiba","year":"1984","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.tips.2017.03.010_bib0180","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/S0006-291X(87)80020-7","article-title":"Mechanism of oxidation of 1-methyl-4-phenyl-2,3-dihydropyridinium (MPDP+)","volume":"144","author":"Korytowski","year":"1987","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.tips.2017.03.010_bib0185","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1021\/jm00148a010","article-title":"Studies on the 1-methyl-4-phenyl-2,3-dihydropyridinium species 2,3-MPDP+, the monoamine oxidase catalyzed oxidation product of the nigrostriatal toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)","volume":"28","author":"Peterson","year":"1985","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.tips.2017.03.010_bib0190","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1038\/nmeth940","article-title":"Mitochondrial PO2 measured by delayed fluorescence of endogenous protoporphyrin IX","volume":"3","author":"Mik","year":"2006","journal-title":"Nat. Methods"},{"key":"10.1016\/j.tips.2017.03.010_bib0195","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1111\/j.1471-4159.2010.06801.x","article-title":"Cellular localization of the organic cation transporters, OCT1 and OCT2, in brain microvessel endothelial cells and its implication for MPTP transport across the blood-brain barrier and MPTP-induced dopaminergic toxicity in rodents","volume":"114","author":"Lin","year":"2010","journal-title":"J. Neurochem."},{"key":"10.1016\/j.tips.2017.03.010_bib0200","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s12640-013-9449-5","article-title":"MALDI mass spectrometry imaging of 1-methyl-4-phenylpyridinium (MPP+) in mouse brain","volume":"25","author":"Kadar","year":"2014","journal-title":"Neurotox. Res."},{"key":"10.1016\/j.tips.2017.03.010_bib0205","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/ng1097-206","article-title":"Increased stress response and beta-phenylethylamine in MAOB-deficient mice","volume":"17","author":"Grimsby","year":"1997","journal-title":"Nat. Genet."},{"key":"10.1016\/j.tips.2017.03.010_bib0210","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1124\/dmd.115.063594","article-title":"Activation and deactivation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by cytochrome P450 enzymes and flavin-containing monooxygenases in common marmosets (Callithrix jacchus)","volume":"43","author":"Uehara","year":"2015","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.tips.2017.03.010_bib0215","doi-asserted-by":"crossref","first-page":"4436","DOI":"10.1074\/jbc.M112.402123","article-title":"Metabolism of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by mitochondrion-targeted cytochrome P450 2D6: implications in Parkinson disease","volume":"288","author":"Bajpai","year":"2013","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.tips.2017.03.010_bib0220","doi-asserted-by":"crossref","first-page":"e84413","DOI":"10.1371\/journal.pone.0084413","article-title":"CYP2D6*4 allele polymorphism increases the risk of Parkinson\u2019s disease: evidence from meta-analysis","volume":"8","author":"Lu","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.tips.2017.03.010_bib0225","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1002\/ana.20051","article-title":"CYP2D6 polymorphism, pesticide exposure, and Parkinson\u2019s disease","volume":"55","author":"Elbaz","year":"2004","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.tips.2017.03.010_bib0230","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/sj.tpj.6500285","article-title":"Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity","volume":"5","author":"Ingelman-Sundberg","year":"2005","journal-title":"Pharmacogenomics J."},{"key":"10.1016\/j.tips.2017.03.010_bib0235","doi-asserted-by":"crossref","first-page":"248608","DOI":"10.1155\/2013\/248608","article-title":"Metabolite profile resulting from the activation\/inactivation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and 2-methyltetrahydro-\u03b2-carboline by oxidative enzymes","volume":"2013","author":"Herraiz","year":"2013","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.tips.2017.03.010_bib0240","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.taap.2006.06.003","article-title":"Comparative aromatic hydroxylation and N-demethylation of MPTP neurotoxin and its analogs, N-methylated beta-carboline and isoquinoline alkaloids, by human cytochrome P450 2D6","volume":"216","author":"Herraiz","year":"2006","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.tips.2017.03.010_bib0245","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/0014-2999(85)90331-0","article-title":"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxicity in mice is enhanced by pretreatment with diethyldithiocarbamate","volume":"119","author":"Corsini","year":"1985","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.tips.2017.03.010_bib0250","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1111\/j.1460-9568.2010.07142.x","article-title":"Cytochrome P450 2D6 enzyme neuroprotects against 1-methyl-4-phenylpyridinium toxicity in SH-SY5Y neuronal cells","volume":"31","author":"Mann","year":"2010","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.tips.2017.03.010_bib0255","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/0014-2999(90)90592-T","article-title":"Effects of N-methylmercaptoimidazole on the disposition of MPTP and its metabolites in mice","volume":"180","author":"Chiba","year":"1990","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.tips.2017.03.010_bib0260","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1016\/0024-3205(89)90072-6","article-title":"Tissue concentrations of MPTP and MPP+ in relation to catecholamine depletion after the oral or subcutaneous administration of MPTP to mice","volume":"45","author":"Fuller","year":"1989","journal-title":"Life Sci."},{"key":"10.1016\/j.tips.2017.03.010_bib0265","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.nbd.2014.10.016","article-title":"Increased expression of the dopamine transporter leads to loss of dopamine neurons, oxidative stress and l-DOPA reversible motor deficits","volume":"74","author":"Masoud","year":"2015","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.tips.2017.03.010_bib0270","doi-asserted-by":"crossref","first-page":"9977","DOI":"10.1073\/pnas.1402134111","article-title":"Increased vesicular monoamine transporter enhances dopamine release and opposes Parkinson disease-related neurodegeneration in vivo","volume":"111","author":"Lohr","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.tips.2017.03.010_bib0275","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1046\/j.1471-4159.1998.70051973.x","article-title":"Increased MPTP neurotoxicity in vesicular monoamine transporter 2 heterozygote knockout mice","volume":"70","author":"Gainetdinov","year":"1998","journal-title":"J. Neurochem."},{"key":"10.1016\/j.tips.2017.03.010_bib0280","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1124\/pr.114.010397","article-title":"Regulation of the dopamine and vesicular monoamine transporters: pharmacological targets and implications for disease","volume":"67","author":"German","year":"2015","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.tips.2017.03.010_bib0285","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.neuropharm.2013.08.033","article-title":"Reduced vesicular storage of catecholamines causes progressive degeneration in the locus ceruleus","volume":"76","author":"Taylor","year":"2014","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.tips.2017.03.010_bib0290","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1016\/j.neurobiolaging.2012.12.020","article-title":"Analysis of vesicular monoamine transporter 2 polymorphisms in Parkinson\u2019s disease","volume":"34","author":"Brighina","year":"2013","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.tips.2017.03.010_bib0295","first-page":"903164","article-title":"Polymorphism in the vesicular monoamine transporter 2 gene decreases the risk of Parkinson\u2019s disease in Han Chinese men","volume":"2015","author":"Yang","year":"2015","journal-title":"Parkinsons Dis."},{"key":"10.1016\/j.tips.2017.03.010_bib0300","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1096\/fj.06-5864fje","article-title":"Developmental exposure to the pesticide dieldrin alters the dopamine system and increases neurotoxicity in an animal model of Parkinson\u2019s disease","volume":"20","author":"Richardson","year":"2006","journal-title":"FASEB J."},{"key":"10.1016\/j.tips.2017.03.010_bib0305","doi-asserted-by":"crossref","first-page":"10736","DOI":"10.1074\/jbc.R112.410530","article-title":"Calcium, bioenergetics, and neuronal vulnerability in Parkinson\u2019s disease","volume":"288","author":"Surmeier","year":"2013","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.tips.2017.03.010_bib0310","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1016\/j.cellsig.2013.09.004","article-title":"Homer1 knockdown protects dopamine neurons through regulating calcium homeostasis in an in vitro model of Parkinson\u2019s disease","volume":"25","author":"Chen","year":"2013","journal-title":"Cell Signal."},{"key":"10.1016\/j.tips.2017.03.010_bib0315","doi-asserted-by":"crossref","first-page":"146","DOI":"10.3389\/fnana.2014.00146","article-title":"Calbindin content and differential vulnerability of midbrain efferent dopaminergic neurons in macaques","volume":"8","author":"Dopeso-Reyes","year":"2014","journal-title":"Front. Neuroanat."},{"key":"10.1016\/j.tips.2017.03.010_bib0320","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s12035-012-8332-3","article-title":"The neuroprotective effect of overexpression of calbindin-D(28k) in an animal model of Parkinson\u2019s disease","volume":"47","author":"Yuan","year":"2013","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.tips.2017.03.010_bib0325","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1093\/brain\/awt134","article-title":"Parkinson\u2019s disease is associated with altered expression of CaV1 channels and calcium-binding proteins","volume":"136","author":"Hurley","year":"2013","journal-title":"Brain"},{"key":"10.1016\/j.tips.2017.03.010_bib0330","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1113\/jphysiol.1993.sp019742","article-title":"Nifedipine- and omega-conotoxin-sensitive Ca2+ conductances in guinea-pig substantia nigra pars compacta neurones","volume":"466","author":"Nedergaard","year":"1993","journal-title":"J. Physiol."},{"key":"10.1016\/j.tips.2017.03.010_bib0335","doi-asserted-by":"crossref","first-page":"11011","DOI":"10.1523\/JNEUROSCI.2519-09.2009","article-title":"Robust pacemaking in substantia nigra dopaminergic neurons","volume":"29","author":"Guzman","year":"2009","journal-title":"J. Neurosci."},{"key":"10.1016\/j.tips.2017.03.010_bib0340","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s00441-004-0956-9","article-title":"Stages in the development of Parkinson\u2019s disease-related pathology","volume":"318","author":"Braak","year":"2004","journal-title":"Cell Tissue Res."},{"key":"10.1016\/j.tips.2017.03.010_bib0345","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1113\/jphysiol.1996.sp021419","article-title":"Calcium-dependent prepotentials contribute to spontaneous activity in rat tuberomammillary neurons","volume":"493","author":"Stevens","year":"1996","journal-title":"J. Physiol."},{"key":"10.1016\/j.tips.2017.03.010_bib0350","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.mcn.2015.08.012","article-title":"A concerted action of L- and T-type Ca2+ channels regulates locus coeruleus pacemaking","volume":"68","author":"Matschke","year":"2015","journal-title":"Mol. Cell. Neurosci."},{"key":"10.1016\/j.tips.2017.03.010_bib0355","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1113\/jphysiol.2005.084632","article-title":"Functional properties of dopaminergic neurones in the mouse olfactory bulb","volume":"564","author":"Pignatelli","year":"2005","journal-title":"J. Physiol."},{"key":"10.1016\/j.tips.2017.03.010_bib0360","doi-asserted-by":"crossref","first-page":"7401","DOI":"10.1523\/JNEUROSCI.0143-10.2010","article-title":"Pacemaking in dopaminergic ventral tegmental area neurons: depolarizing drive from background and voltage-dependent sodium conductances","volume":"30","author":"Khaliq","year":"2010","journal-title":"J. Neurosci."},{"key":"10.1016\/j.tips.2017.03.010_bib0365","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.neuroscience.2011.08.045","article-title":"The role of calcium and mitochondrial oxidant stress in the loss of substantia nigra pars compacta dopaminergic neurons in Parkinson\u2019s disease","volume":"198","author":"Surmeier","year":"2011","journal-title":"Neuroscience"},{"key":"10.1016\/j.tips.2017.03.010_bib0370","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1038\/nature05865","article-title":"\u2018Rejuvenation\u2019 protects neurons in mouse models of Parkinson\u2019s disease","volume":"447","author":"Chan","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.tips.2017.03.010_bib0375","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.nbd.2011.04.007","article-title":"The L-type channel antagonist isradipine is neuroprotective in a mouse model of Parkinson\u2019s disease","volume":"43","author":"Ilijic","year":"2011","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.tips.2017.03.010_bib0380","first-page":"697404","article-title":"Reduced risk of Parkinson\u2019s disease in users of calcium channel blockers: a meta-analysis","volume":"2015","author":"Gudala","year":"2015","journal-title":"Int. J. Chronic Dis."},{"key":"10.1016\/j.tips.2017.03.010_bib0385","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1002\/pds.3781","article-title":"Calcium channel blocker use and risk of Parkinson\u2019s disease: a meta-analysis","volume":"24","author":"Lang","year":"2015","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"10.1016\/j.tips.2017.03.010_bib0390","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1002\/mds.25135","article-title":"Living on the edge with too many mouths to feed: why dopamine neurons die","volume":"27","author":"Bolam","year":"2012","journal-title":"Mov. Disord."},{"key":"10.1016\/j.tips.2017.03.010_bib0395","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1523\/JNEUROSCI.4029-08.2009","article-title":"Single nigrostriatal dopaminergic neurons form widely spread and highly dense axonal arborizations in the neostriatum","volume":"29","author":"Matsuda","year":"2009","journal-title":"J. Neurosci."},{"key":"10.1016\/j.tips.2017.03.010_bib0400","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.neuroscience.2008.01.046","article-title":"Stereological estimates of dopaminergic, GABAergic and glutamatergic neurons in the ventral tegmental area, substantia nigra and retrorubral field in the rat","volume":"152","author":"Nair-Roberts","year":"2008","journal-title":"Neuroscience"},{"key":"10.1016\/j.tips.2017.03.010_bib0405","doi-asserted-by":"crossref","first-page":"152","DOI":"10.3389\/fnana.2014.00152","article-title":"Molecular determinants of selective dopaminergic vulnerability in Parkinson\u2019s disease: an update","volume":"8","author":"Brichta","year":"2014","journal-title":"Front. Neuroanat."},{"key":"10.1016\/j.tips.2017.03.010_bib0410","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1002\/cne.10165","article-title":"Comparison of the basal ganglia in rats, marmosets, macaques, baboons, and humans: volume and neuronal number for the output, internal relay, and striatal modulating nuclei","volume":"445","author":"Hardman","year":"2002","journal-title":"J. Comp. Neurol."},{"key":"10.1016\/j.tips.2017.03.010_bib0415","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3389\/fncom.2013.00013","article-title":"The energy cost of action potential propagation in dopamine neurons: clues to susceptibility in Parkinson\u2019s disease","volume":"7","author":"Pissadaki","year":"2013","journal-title":"Front. Comput. Neurosci."},{"key":"10.1016\/j.tips.2017.03.010_bib0420","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.neuron.2012.08.019","article-title":"Synaptic energy use and supply","volume":"75","author":"Harris","year":"2012","journal-title":"Neuron"},{"key":"10.1016\/j.tips.2017.03.010_bib0425","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1093\/brain\/aww230","article-title":"Like prions: the propagation of aggregated tau and \u03b1-synuclein in neurodegeneration","volume":"140","author":"Goedert","year":"2017","journal-title":"Brain"},{"key":"10.1016\/j.tips.2017.03.010_bib0430","first-page":"S53","article-title":"The synucleinopathies: twenty years on","volume":"7","author":"Goedert","year":"2017","journal-title":"J. Parkinsons Dis."},{"key":"10.1016\/j.tips.2017.03.010_bib0435","first-page":"S73","article-title":"Neuropathological staging of brain pathology in sporadic Parkinson\u2019s disease: separating the wheat from the chaff","volume":"7","author":"Braak","year":"2017","journal-title":"J. Parkinsons Dis."},{"key":"10.1016\/j.tips.2017.03.010_bib0440","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1111\/jnc.12226","article-title":"Oxidative and nitrative alpha-synuclein modifications and proteostatic stress: implications for disease mechanisms and interventions in synucleinopathies","volume":"125","author":"Schildknecht","year":"2013","journal-title":"J. Neurochem."},{"key":"10.1016\/j.tips.2017.03.010_bib0445","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1046\/j.1471-4159.2000.740721.x","article-title":"Alpha-synuclein up-regulation in substantia nigra dopaminergic neurons following administration of the parkinsonian toxin MPTP","volume":"74","author":"Vila","year":"2000","journal-title":"J. Neurochem."},{"key":"10.1016\/j.tips.2017.03.010_bib0450","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/j.nbd.2005.05.028","article-title":"Alpha-synuclein expression in the substantia nigra of MPTP-lesioned non-human primates","volume":"20","author":"Purisai","year":"2005","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.tips.2017.03.010_bib0455","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1002\/emmm.201302475","article-title":"Caudo-rostral brain spreading of \u03b1-synuclein through vagal connections","volume":"5","author":"Ulusoy","year":"2013","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.tips.2017.03.010_bib0460","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1093\/brain\/awv376","article-title":"Brain propagation of transduced \u03b1-synuclein involves non-fibrillar protein species and is enhanced in \u03b1-synuclein null mice","volume":"139","author":"Helwig","year":"2016","journal-title":"Brain"},{"key":"10.1016\/j.tips.2017.03.010_bib0465","doi-asserted-by":"crossref","first-page":"2721","DOI":"10.1172\/JCI64502","article-title":"shRNA targeting \u03b1-synuclein prevents neurodegeneration in a Parkinson\u2019s disease model","volume":"125","author":"Zharikov","year":"2015","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.tips.2017.03.010_bib0470","doi-asserted-by":"crossref","first-page":"14524","DOI":"10.1073\/pnas.172514599","article-title":"Resistance of alpha-synuclein null mice to the parkinsonian neurotoxin MPTP","volume":"99","author":"Dauer","year":"2015","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.tips.2017.03.010_bib0475","doi-asserted-by":"crossref","first-page":"e0131281","DOI":"10.1371\/journal.pone.0131281","article-title":"Targeted overexpression of \u03b1-synuclein by rAAV2\/1 vectors induces progressive nigrostriatal degeneration and increases vulnerability to MPTP in mouse","volume":"10","author":"Song","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.tips.2017.03.010_bib0480","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1002\/cne.23901","article-title":"Brain region-dependent differential expression of alpha-synuclein","volume":"524","author":"Taguchi","year":"2016","journal-title":"J. Comp. Neurol."},{"key":"10.1016\/j.tips.2017.03.010_bib0485","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0079-6123(10)83007-9","article-title":"Role of post-translational modifications in modulating the structure, function and toxicity of alpha-synuclein: implications for Parkinson\u2019s disease pathogenesis and therapies","volume":"183","author":"Oueslati","year":"2010","journal-title":"Prog. Brain Res."},{"key":"10.1016\/j.tips.2017.03.010_bib0490","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1097\/NEN.0b013e318180f0bd","article-title":"Pathologic modifications of alpha-synuclein in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated squirrel monkeys","volume":"67","author":"McCormack","year":"2008","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.tips.2017.03.010_bib0495","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.neuron.2009.01.033","article-title":"Interplay between cytosolic dopamine, calcium, and alpha-synuclein causes selective death of substantia nigra neurons","volume":"62","author":"Mosharov","year":"2009","journal-title":"Neuron"},{"key":"10.1016\/j.tips.2017.03.010_bib0500","series-title":"Parkinson\u2019s Disease: Molecular and Therapeutic Insights from Model Systems","first-page":"147","article-title":"The MPTP mouse model of Parkinson\u2019s disease: the true, the false, and the unknown","author":"Jackson-Lewis","year":"2008"},{"key":"10.1016\/j.tips.2017.03.010_bib0505","doi-asserted-by":"crossref","first-page":"38884","DOI":"10.1074\/jbc.M205518200","article-title":"Effect of mutant alpha-synuclein on dopamine homeostasis in a new human mesencephalic cell line","volume":"277","author":"Lotharius","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.tips.2017.03.010_bib0510","first-page":"777","article-title":"Dopamine-modified alpha-synuclein blocks chaperone-mediated autophagy","volume":"118","author":"Martinez-Vicente","year":"2008","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.tips.2017.03.010_bib0515","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.neuroscience.2011.10.057","article-title":"Neurotoxin-based models of Parkinson\u2019s disease","volume":"211","author":"Bov\u00e9","year":"2012","journal-title":"Neuroscience"},{"key":"10.1016\/j.tips.2017.03.010_bib0520","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/nprot.2006.342","article-title":"Protocol for the MPTP mouse model of Parkinson\u2019s disease","volume":"2","author":"Jackson-Lewis","year":"2007","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.tips.2017.03.010_bib0525","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1093\/toxsci\/kfu199","article-title":"Adverse outcome pathway (AOP) development I: strategies and principles","volume":"142","author":"Villeneuve","year":"2014","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.tips.2017.03.010_bib0530","first-page":"4691","article-title":"Investigation into experimental toxicological properties of plant protection products having a potential link to Parkinson\u2019s disease and childhood leukaemia","volume":"15","author":"Ockleford","year":"2017","journal-title":"EFSA J."}],"container-title":["Trends in Pharmacological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165614717300780?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165614717300780?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T19:47:53Z","timestamp":1750189673000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165614717300780"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":106,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["S0165614717300780"],"URL":"https:\/\/doi.org\/10.1016\/j.tips.2017.03.010","relation":{},"ISSN":["0165-6147"],"issn-type":[{"value":"0165-6147","type":"print"}],"subject":[],"published":{"date-parts":[[2017,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tipping Points and Endogenous Determinants of Nigrostriatal Degeneration by MPTP","name":"articletitle","label":"Article Title"},{"value":"Trends in Pharmacological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tips.2017.03.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}